Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 28, 2011

Lucigen's New PCR Kit to Include TriLink's CleanAmp dNTPs

  • Lucigen will use TriLink BioTechnologies' CleanAmp™ dNTPs in its new PCR kit, Taq98™ Hot Start 2X MasterMix. The kit is expected to reach the market next month under a licensing agreement signed by the companies.

    Introduced to market in April, TriLink’s CleanAmp dNTPs are designed to perform hot start PCR, with the goal of reducing mis-priming, primer dimer formation, and other common missteps. CleanAmp dNTPs reportedly allow improved amplicon yield in endpoint PCR and earlier quantification cycle (Cq) values in fast cycling real-time PCR.

    Lucigen’s Taq98 Hot Start 2X Master Mix is expected to be available for sale in mid-August. The PCR kit is designed for customers seeking to amplify difficult DNA templates, including targets with >70% GC content. “The addition of the Hot Start feature has significantly increased the market for this product," states Jeff Williams, Lucigen’s president. Lucigen portfolio of PCR kits includes EconoTaq® DNA Polymerase and EconoTaq® PLUS 2X Master Mixes.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »